Castle Biosciences Inc (CSTL) Stock Price & Analysis

Castle Biosciences Inc (CSTL) rose 0.80% to USD 32.91 as of September 8, 2026 at 10:48 UTC, according to Nexqual real-time market data.

CSTL last closed at USD 32.91; the session ranged USD 31.99–33.21 on volume of 187,725 shares. Market capitalization is —, with a 52-week range of USD 17.72–44.28 (NGM). Source: Nexqual, September 8, 2026 at 10:48 UTC.

Key Statistics (as of September 8, 2026 at 10:48 UTC)

Technical Analysis (CSTL)

Nexqual's technical model rates CSTL "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 10:48 UTC.

From Castle Biosciences Inc's Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• Our proprietary tests, which were first marketed prior to May 6, 2024, remain approved by and under the oversight of the NYSDOH, and we continue to believe that changes in FDA's regulatory approach to LDTs will have no material impact on our existing test offerings.
• Medical Device Regulatory Framework Although we currently market our proprietary testing products as LDTs, which are currently subject to enforcement discretion, we could be subject to FDA compliance obligations in the future.
• DecisionDx-Melanoma DecisionDx-Melanoma is our proprietary risk stratification gene expression profile ("GEP") test designed to predict the likelihood of a positive sentinel lymph node and the risk of metastasis or recurrence for patients diagnosed with invasive cutaneous melanoma ("CM"), a deadly skin cancer.
• DecisionDx-SCC DecisionDx‑SCC is our proprietary GEP test designed for use in patients with cutaneous squamous cell carcinoma ("SCC"), the second most common form of skin cancer, with one or more risk factors (also referred to as "high-risk" SCC).

Partnerships

• If these suppliers can no longer provide us with the materials we need to perform our test services, they do not meet our quality specifications, or we cannot obtain acceptable substitute materials, our business would likely be negatively affected. 12 Table of Contents License Agreement with The Washington University In November 2009, we entered into a license agreement (the "License Agreement") with The Washington University in St.
• In June 2025, we entered into a collaboration and license agreement with SciBase Holding AB ("SciBase") to develop and commercialize diagnostic tests for dermatologic diseases, beginning with atopic dermatitis.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 10:48 UTC. This page is informational and not investment advice.